✦ LIBER ✦

6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)

✍ Scribed by Grossi, F.; Defferrari, C.; Brianti, A.; Dal Bello, M.G.; Loprevite, M.; Catania, G.; Pronzato, P.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The relevance of stable disease (SD) as

✍ Grossi, F.; Sini, C.; Barletta, G.; Rijavec, E.; Genova, C.; Dal Bello, G.; Pron 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

6625 POSTER Gefitinib (G) treatment outc

✍ Grossi, F.; Brianti, A.; Defferrari, C.; Dal Bello, M.G.; Loprevite, M.; Catania 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

9086 POSTER Effectiveness of Bevacizumab

✍ Thomas, S.; Ravelo, A.; Yu, E.; Dranitsaris, G.; Kalberer, T.; Beegle, N. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Adoptive immunotherapy as either neo-adj

✍ Ratto, G.B.; Melioli, G.; Mereu, C.; Fantino, G.; Tassara, E.; Verna, A.; Ponte, 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 149 KB

9101 POSTER Pre-planned Subgroup Analyse

✍ Zhang, L.; Ma, S.L.; Song, X.Q.; Cheng, Y.; Huang, C.; Yang, S.J.; Liu, X.Q.; Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB